Humulin N Kwikpen (Insulin Human (Rdna))

Humulin N Kwikpen is indicated for basal insulin therapy in the management of diabetes, providing a steady background level of insulin to complement mealtime rapid‑acting insulins.

• Type 1 diabetes mellitus as part of a comprehensive insulin regimen.
• Type 2 diabetes mellitus when basal insulin is required to achieve glycaemic targets.
• Adults and pediatric patients (≥6 years) who need once‑daily long‑acting insulin.
• Situations where a prefilled pen device is preferred for ease of self‑administration.
• Patients transitioning from intermediate‑acting insulin preparations to a more predictable basal insulin.

• Humulin N Kwikpen contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers the tyrosine kinase pathway, promoting translocation of GLUT‑4 transporters and increasing glucose uptake in peripheral tissues. In the liver, it suppresses gluconeogenesis and glycogenolysis, thereby reducing endogenous glucose production and lowering circulating blood glucose concentrations.

Like all insulin products, Humulin N Kwikpen may be associated with adverse reactions that range from mild to severe.

Common

• Injection site pain, redness or swelling.
• Mild hypoglycaemia (blood glucose <70 mg/dL) with symptoms such as shakiness, sweating, or hunger.
• Weight gain related to improved glycaemic control.
• Lipodystrophy at the injection site with repeated use.

Serious

• Severe hypoglycaemia requiring assistance.
• Allergic reactions including urticaria, angio‑edema or anaphylaxis.
• Edema or fluid retention leading to peripheral swelling.
• Hypersensitivity to any component of the formulation.

Healthcare providers should consider several precautions before initiating Humulin N Kwikpen to ensure safe and effective use.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Adjust dose when patients are ill, fasting, or experiencing changes in physical activity.
• Monitor blood glucose closely during pregnancy; insulin requirements may change.
• Educate patients on recognizing and treating hypoglycaemia promptly.
• Avoid use in individuals with known hypersensitivity to human insulin or any excipients.
• Review concomitant medications that can mask hypoglycaemia symptoms.

Humulin N Kwikpen can interact with other medicines, affecting glucose control or increasing the risk of adverse events.

Avoid

• Concurrent use of other basal insulins or high‑dose insulin secretagogues without dose adjustment.
• Beta‑blockers that may blunt hypoglycaemia warning signs.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycaemia risk.
• Corticosteroids, which may raise insulin requirements.
• Thiazide diuretics, which can affect glucose tolerance.
• Alcohol consumption, which may cause delayed hypoglycaemia.